From Anticoagulant to Research Tool: An Overview of the Structure and Applications of Heparin (Hep)

What Is Heparin?

Heparin (Heparin, abbreviated as Hep) is a highly sulfated glycosaminoglycan (GAG) and essentially a long-chain polysaccharide composed of repeating disaccharide units.

In vivo, heparin is synthesized mainly by mast cells and basophils and stored in their intracellular granules. Although its physiological roles in the body have not been fully elucidated, it is known to be involved in processes such as inflammatory responses, antimicrobial defense, and regulation of the local microenvironment.

Heparin is closely related to heparan sulfate (HS), which is widely distributed on cell surfaces and within the extracellular matrix. Heparin can be regarded as a highly sulfated, specialized form of HS: the two belong to the same class of polysaccharides, but differ in their degree of sulfation and in the composition of their sugar residues. In tissues, HS is the predominant GAG on cell surfaces and in the extracellular matrix, whereas “heparin” mainly exists as a highly sulfated polysaccharide stored in mast cell granules, with very little present in a free form.

Discovery and Sources: A Brief Overview

(1) Discovery and Naming

In 1916, researchers identified a substance with strong anticoagulant activity in extracts of animal liver and named it heparin. Subsequent purification, structural characterization, and animal studies gradually established that heparin is a highly negatively charged polysaccharide. Clinical use as an anticoagulant began in the 1930s–1940s.

(2) Industrial Sources

In modern industrial production, heparin is obtained primarily from porcine intestinal mucosa. In some countries, small intestine or lung tissue from cattle, sheep, and other animals is also used as a source. Through extraction, purification, and fractionation, heparin preparations with different molecular weights and potencies can be produced. Their anticoagulant activity is generally expressed as potency (IU/mg).

Structural Features of Heparin

1. Basic Backbone

Heparin is composed of repeating disaccharide units, each typically containing:

(a) An amino sugar: D-glucosamine (GlcN)

(b) A uronic acid: predominantly L-iduronic acid (IdoA), with a small amount of D-glucuronic acid (GlcA)

2. High Degree of Sulfation and Strong Negative Charge

(a) Multiple amino and hydroxyl positions can be sulfated, and on average, each disaccharide unit in heparin carries more than one sulfate group;

(b) Uronic acid residues carry carboxyl groups, giving the entire polysaccharide chain a high density of negative charges.

This high degree of sulfation and high negative charge density are the key structural features of heparin and form the basis for its high-affinity binding to a wide range of proteins, particularly antithrombin and other anticoagulant proteins.

How Does Heparin Exert Its Anticoagulant Effect?

Heparin itself is not a drug that “directly dissolves” thrombi; instead, it works by potentiating the body’s endogenous anticoagulant system.

1. Binding to Antithrombin to Amplify Its Inhibitory Effect

(a) A specific pentasaccharide sequence on the heparin chain binds antithrombin (AT) with high affinity;

(b) This binding induces a conformational change in AT, markedly increasing its inhibitory rate toward thrombin (factor IIa) and activated factor Xa (which can be understood as “making AT work faster and more efficiently”).

2. Inhibiting Key Coagulation Factors and Blocking the Coagulation Cascade

(a) Antithrombin in complex with heparin mainly inhibits thrombin (IIa) and factor Xa, and also acts on factors IXa, XIa, and others;

(b) These factors occupy critical nodes within the coagulation cascade; once inhibited, the overall risk of thrombus formation is significantly reduced.

In simplified terms:

Heparin = helps endogenous anticoagulant proteins apply a more effective “brake” on the coagulation process.

Unfractionated Heparin vs. Low-Molecular-Weight Heparin

In both clinical practice and research, heparin is most commonly discussed in two major forms: unfractionated heparin and low-molecular-weight heparin.

1. Unfractionated Heparin (UFH)

(Unfractionated Heparin, UFH, also referred to as “standard heparin” or “unfractionated heparin”)

1. Obtained directly from animal tissue extracts without further fractionation by molecular weight;

2. Exhibits a broad molecular weight distribution, roughly 3–30 kDa;

3. Typically administered by intravenous infusion or subcutaneous injection, with rapid onset of action and a relatively short half-life;

4. Shows considerable interindividual variability in anticoagulant response, so dosing often needs to be guided and adjusted based on aPTT or anti-Xa activity monitoring.

2. Low-Molecular-Weight Heparin (LMWH)

(Low-Molecular-Weight Heparin, LMWH)

1. Produced by partial chemical or enzymatic depolymerization of standard heparin, resulting in a lower and more narrowly distributed average molecular weight (commonly around 4–6 kDa);

2. Administered mainly by subcutaneous injection, with more predictable pharmacokinetics. Routine aPTT monitoring is generally not required; in special populations such as those with markedly impaired renal function, pregnant patients, or individuals with extreme body weight, anti-Xa activity monitoring may be considered according to guidelines;

3. Compared with UFH, LMWH has relatively stronger inhibitory activity against factor Xa and relatively weaker activity against thrombin. The overall risk of certain adverse events (such as HIT) is lower, although not completely eliminated.

In real-world clinical practice, UFH and various LMWH products are selected for different clinical scenarios according to disease conditions and relevant treatment guidelines.

Overview of the Clinical Applications of Heparin (Why It Is So Important)

From the perspective of “drug history,” heparin’s most important role is as a classic anticoagulant agent. In brief, it is mainly used for:

1. Prevention and treatment of venous thromboembolism (VTE)

For example, the prophylaxis and treatment of high-risk conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

2. Anticoagulant therapy in cardiovascular diseases

Including acute coronary syndromes such as acute myocardial infarction and unstable angina, where heparin is often used in combination with antiplatelet agents to prevent the formation or extension of coronary thrombosis.

3. Anticoagulation in extracorporeal circulation and blood purification procedures

In settings such as cardiopulmonary bypass in cardiac surgery, hemodialysis, and ECMO, heparin is used to prevent clotting of blood within extracorporeal circuits and devices.

4. Anticoagulation in certain laboratory and transfusion procedures

Added as an anticoagulant to some blood samples to maintain them in a non-clotted state ex vivo, facilitating analytical testing or cell culture.

Note: In clinical practice, the specific indications, dosing regimens, and monitoring strategies for heparin and low-molecular-weight heparin must be determined by physicians based on clinical guidelines and individual patient factors. These details are beyond the scope of this popular science article.

Safety and Precautions

While recognizing its clinical value, it is also important to understand the main risks associated with heparin.

1. Bleeding Risk

1. The most common and also the most important adverse reaction. It may present as subcutaneous bruising, gum bleeding, or gastrointestinal bleeding, and in severe cases, intracranial hemorrhage and other serious events;

2. The risk is related to dose, duration of therapy, underlying diseases, and concomitant medications, and should be evaluated comprehensively through clinical observation and coagulation parameters.

2. Heparin-Induced Thrombocytopenia (HIT)

1. An immune-mediated adverse reaction characterized by a decrease in platelet count with a paradoxical increase in thrombotic risk;

2. It occurs more frequently with unfractionated heparin, while the risk is lower with low-molecular-weight heparin but still requires vigilance;

3. In clinical use, platelet counts are typically monitored over the course of therapy.

3. Other Adverse Reactions with Long-Term Use

1. Long-term, high-dose heparin therapy may increase the risk of osteoporosis and fractures;

2. Other possible reactions include rash, injection-site reactions, and alopecia.

In clinical settings, if severe bleeding occurs, protamine can be used under specialist supervision to partially or completely neutralize heparin (its neutralizing capacity for low-molecular-weight heparin is relatively limited).

Important: All clinical information in this article is intended solely for basic education and understanding and does not constitute specific diagnostic or therapeutic advice. For real medical conditions or treatment decisions, the recommendations of qualified clinicians and authoritative guidelines should always prevail.

Applications of Heparin in Research and Experimental Settings

For many students, educators, researchers, and industrial users, heparin is more often a tool for experiments and R&D than a drug. Below, its major research applications are summarized by common product type.

1. Basic Heparin and Its Salts

(1) Unfractionated heparin

Used as a polysaccharide raw material in in vitro anticoagulation models, enzyme kinetics studies, and investigations of polysaccharide–protein interactions.

(2) Heparin sodium, heparin calcium, heparin lithium, and other salts

Different cation forms exhibit slight differences in solubility, formulation design, and material-binding properties, and can be used for:

(a) Anticoagulant/stabilizing components in cell culture media or buffer systems;

(b) In vitro blood-contact experiments;

(c) Comparative studies in systems containing different metal ions.

(3) Heparin from different animal sources (e.g., porcine, bovine, ovine)

Used to compare structural, immunogenic, or bioactivity differences among heparins derived from different species.

2. LMWH Raw Materials and Clinical-Type Preparations

(1) Low-molecular-weight heparin raw materials fractionated by average molecular weight

For example, 2–3 kDa, 6–9 kDa, etc., used for:

(a) Studying the relationship between molecular weight and anticoagulant activity;

(b) Exploring the behavior of “short-chain heparins” on material surfaces, in nanocarriers, or in controlled-release drug delivery systems.

(2) Low-molecular-weight heparin preparations analogous to clinical products

(e.g., enoxaparin, dalteparin, nadroparin), commonly used for:

(a) In vitro models of pharmacokinetics and pharmacodynamics;

(b) Comparative studies of chemical and enzymatic degradation behavior;

(c) Reference standards in the development of generic drugs or novel formulations.

3. Structurally Modified Heparins (Desulfation, Acetylation, etc.)

(1) 2-O-, 6-O-, and N-desulfated heparins

Sulfate groups are selectively removed at specific positions and can be used to:

(a) Investigate how sulfation at the corresponding positions affects AT binding, protein interactions, and anticoagulant activity;

(b) Construct heparins with weakened or near-absent anticoagulant activity for studying other biological effects, such as anti-inflammatory or antitumor properties.

(2) N-acetyl heparin, N-acetyl-O-sulfated heparin, and related derivatives

By modulating charge and structure via N-acetylation, these derivatives can:

(a) Substitute strongly anticoagulant heparin to provide safer conditions for in vitro experiments;

(b) Form libraries of “weakly anticoagulant/non-anticoagulant heparins” for screening new biological functions.

4. Heparan Sulfate (HS) and Its Derivatives

(1) HS backbone and HS sodium salts

These more closely resemble physiological forms on cell surfaces and in the extracellular matrix and are commonly used for:

(a) Studies of cell signaling, adhesion, and proliferation regulation;

(b) Investigations of interactions between growth factors, chemokines, and GAGs.

(2) Low-molecular-weight HS, desulfated HS, and other derivatives

Used in parallel with heparin derivatives to compare Hep/HS structure–function relationships under different sulfation patterns and molecular weights.

5. Oligosaccharide and Disaccharide Standards (Including Fluorescently Labeled Forms)

(1) Heparin/HS oligosaccharide mixtures, tetrasaccharides, hexasaccharides, octasaccharides, etc.

Mainly used for:

(a) Studying how oligosaccharide chain length affects protein binding, anticoagulant activity, and material properties;

(b) Serving as reference standards for enzymatic digestion products.

(2) Heparin/HS disaccharides and disaccharide standard mixtures

These are common analytical units generated after digestion by heparinases/heparin lyases and are used for:

(a) HPLC/UPLC/LC–MS structural fingerprint analysis;

(b) Determining sulfation patterns and monosaccharide composition.

(3) Fluorescently labeled heparin disaccharides

Introducing a fluorescent group at the disaccharide terminus markedly enhances detection sensitivity, making them suitable for trace-sample analysis and quantitative studies in complex systems.

6. Labeled and Functionalized Heparin Materials

(1) Biotin-labeled heparin/HS – suitable for:

(a) Solid-phase and affinity capture experiments (e.g., pull-down assays, ELISA);

(b) Constructing heparinized surfaces for oriented binding of proteins, cells, or nanoparticles.

(2) Fluorescently labeled heparin/HS – commonly used for:

(a) Visualizing the distribution and uptake of heparin on cells, in tissues, or on material surfaces;

(b) Establishing confocal imaging and flow cytometry–based analytical systems.

(3) Crosslinkable heparins (e.g., methacrylated heparin)

Can be copolymerized with acrylate monomers to prepare heparin-containing hydrogels or coatings for:

(a) Anticoagulant vascular stents and catheter coatings;

(b) Carriers for sustained release of growth factors or drugs;

(c) Cell culture and tissue engineering scaffolds.

7. Heparin Affinity Media, Binding Peptides, and Probes

(1) Heparin affinity chromatography media

Heparin is immobilized on the matrix and used to purify heparin-binding proteins (such as certain growth factors, coagulation factors, and nucleic acid–binding proteins).

(2) Heparin-binding peptides and specific protein probes

These can mimic heparin-binding domains in proteins or serve as recognition molecules for studies of:

(a) Protein–heparin interaction interfaces;

(b) The distribution and function of heparin/HS on the cell surface.

8. Heparin/HS-Related Enzymes, Heparanase, and Inhibitors

(1) Heparinases I/II/III and their mixtures

These enzymes specifically or selectively cleave heparin and HS, generating oligosaccharides containing unsaturated uronic acids, and are used for:

(a) Structural analysis of heparin/HS;

(b) Studies on sulfation patterns and sequence characteristics;

(c) Establishing glycomics analytical methodologies.

(2) Heparanase and its inhibitors

Heparanase mainly participates in the degradation of HS chains and is associated with matrix remodeling, tumor invasion, and inflammatory responses. It is commonly used for:

(a) Studying Hep/HS metabolic pathways;

(b) Exploring potential therapeutic targets related to tumors and inflammation.

9. Heparin-Anticoagulated Plasma Samples

(1) Animal plasma treated with heparin as an anticoagulant (e.g., mouse, rat, pig)

Commonly used for:

(a) In vitro coagulation function assays;

(b) Method validation in thrombosis and inflammation models;

(c) Performance evaluation of diagnostic reagents or instruments.

Summary

Heparin is a highly sulfated, strongly negatively charged glycosaminoglycan that plays an irreplaceable role in the prevention and treatment of thrombosis by enhancing the activity of endogenous anticoagulant factors such as antithrombin. The marked differences between unfractionated heparin and low-molecular-weight heparin in terms of structure, pharmacokinetics, and safety are fundamental to understanding heparin-based drugs.

Around heparin, HS, and their various derivatives, oligosaccharide standards, enzymes, and functionalized materials, a comprehensive toolkit for research has already been established. This toolkit is widely used in thrombosis and vascular biology, glycomics, protein purification, and biomaterials research.

For more detailed information on specific research-use heparin products, please refer to the “Aladdin Heparin and Related Representative Products List” at the end of this article, and map the “common product categories” in this section to the corresponding entries to select products best suited to your research needs.

Aladdin Heparin and Related Representative Products List

Product Category	Subcategory	Aladdin Cat. No.	Name	CAS No.	Specification / Purity	Applications / Features
Basic Heparin	Unfractionated heparin	H1423211	Heparin	9005-49-6	—	Representative unfractionated heparin polysaccharide, suitable as a control for basic research such as in vitro anticoagulation assays, protein binding studies, or material surface modification.
Basic Heparin	Heparin sodium (high potency)	H123383	Heparin sodium	9041-08-1	Moligand™, ≥180 USP units/mg	High-potency heparin sodium close to pharmacopeial standards, used for ATIII/FXa inhibition assays and in vitro anticoagulation models.
Basic Heparin	Heparin sodium (bovine-derived)	H758140	Heparin sodium salt	9041-08-1	≥99%, ≥150 units/mg, from bovine intestinal mucosa	Bovine-derived heparin sodium for comparative studies of species differences, immunogenicity, or regulatory aspects versus porcine/ovine heparin.
Basic Heparin	Heparin sodium (ovine-derived)	H758151	Heparin sodium salt	9041-08-1	≥99%, ≥150 units/mg, from sheep intestinal mucosa	Ovine-derived heparin sodium, used for studies on source-related differences or when a specific animal origin is required.
Basic Heparin	Heparin calcium	H283849	Heparin calcium	37270-89-6	Mw 15000–19000	A clinically common heparin calcium form, used to study the impact of salt form on anticoagulant activity, solubility, and material performance.
Basic Heparin	Heparin lithium	H101523	Heparin lithium	9045-22-1	≥150 USP units/mg	Heparin in the lithium salt form, suitable for comparing physicochemical properties and activity among different cation forms of heparin.
LMWH (Raw Materials)	Low-molecular-weight heparin 2–3 kDa	H758689	Low-molecular-weight heparin	9041-08-1	≥95% (HPLC), Mw: 2,000–3,000	LMWH raw material for comparing anticoagulant activity and pharmacokinetics with unfractionated heparin.
LMWH (Raw Materials)	Low-molecular-weight heparin 6–9 kDa	H758721	Low-molecular-weight heparin	9041-08-1	≥95% (HPLC), Mw: 6,000–9,000	Higher-molecular-weight LMWH, used together with the 2–3 kDa product to study the relationship between molecular weight and activity.
LMWH Preparations	Enoxaparin sodium (USP)	E413286	Enoxaparin sodium	679809-58-6	PharmPure™, USP	A typical clinical LMWH (enoxaparin), suitable as an LMWH anticoagulant drug control.
LMWH Preparations	Enoxaparin sodium (porcine-derived)	H284086	Enoxaparin sodium (from porcine intestine)	9041-08-1	Moligand™	Enoxaparin derived from porcine intestine, used for studies on the influence of animal source and formulation properties.
LMWH Preparations	Dalteparin sodium	H284091	Dalteparin sodium	9041-08-1	Moligand™, anti-Xa potency 110–210 IU/mg	A clinically used LMWH (dalteparin), suitable for comparing anti-Xa/anti-IIa ratios with enoxaparin and other preparations.
LMWH Preparations	Nadroparin calcium	N283851	Nadroparin calcium	37270-89-6	Weight-average Mw: 3600–5000	LMWH in the calcium salt form (nadroparin), used to compare salt forms and differences among LMWH products.
Structurally Modified Heparins	2-O-desulfated heparin	D758157	2-O-Desulfated heparin sodium salt	—	≥95%	Selective removal of 2-O-sulfate groups; used to study the effects of IdoA 2-O-sulfation on anticoagulant activity and protein binding.
Structurally Modified Heparins	6-O-desulfated heparin	D758155	6-O-Desulfated heparin sodium salt	—	≥95%	Removal of 6-O-sulfate groups; used to analyze the role of GlcN 6-O-sulfation in ATIII/protein recognition.
Structurally Modified Heparins	N-desulfated heparin (I-H)	D130947	N-Desulfated heparin (heparin I-H) sodium salt	61932-66-9	≥95%	N-desulfated heparin, an important intermediate for preparing N-acetyl heparin and non-anticoagulant heparins, and for studying the contribution of N-sulfation to activity.
Structurally Modified Heparins	N-acetyl heparin	N462974	N-Acetyl heparin sodium salt	134498-62-7 (free base)	≥90%, mixture of disaccharides	N-acetylated heparin with reduced anticoagulant activity, used for studying biological functions of non-anticoagulant heparins.
Structurally Modified Heparins	N-acetyl-2-O-sulfated heparin (III-A)	N758166	N-Acetyl-2-O-sulfated heparin (heparin III-A) sodium salt	—	≥95%, potency ≤30 IU/mg	Structurally defined type III-A heparin derivative used to construct structure–function models and analyze the effects of 2-O-sulfation and N-acetylation.
Structurally Modified Heparins	N-acetyl-O-sulfated heparin (IV-A)	N130949	N-Acetyl-O-sulfated heparin (heparin IV-A) sodium salt	133686-69-8	Reagent grade	Type IV-A heparin derivative, used alongside III-A to compare functional differences between sulfation patterns.
Heparan Sulfate / HS	Heparan sulfate	H304938	Heparan sulfate	9050-30-0	Potency ≥50 IU/mg	Representative HS backbone, used to compare sulfation degree, anticoagulant activity, and biological functions with heparin.
Heparan Sulfate / HS	Heparan sulfate sodium (high purity)	H758197	Heparan sulfate sodium	57459-72-0	≥98%, potency <20 IU/mg	HS sodium salt with low anticoagulant activity, mainly used in extracellular matrix models and GAG–protein interaction studies.
Heparan Sulfate / HS	Low-molecular-weight heparan sulfate	H758784	Low-molecular-weight heparan sulfate	57459-72-0	≥95% (HPLC), Mw: 2,000–3,000	Low-molecular-weight HS for comparing signaling and cellular behavior differences with heparin/LMWH.
HS Derivatives	2-O-desulfated HS	H758369	2-O-Desulfated heparan sulfate	—	≥95%, potency <10 IU/mg	2-O-desulfated HS, used together with 2-O-desulfated heparin for systematic studies of site-specific desulfation in Hep/HS.
HS Derivatives	N-desulfated HS	N758374	N-Desulfated heparan sulfate (sodium salt)	—	≥95%, potency ≤10 IU/mg	N-desulfated HS, used to elucidate the importance of N-sulfate groups in HS functions such as growth factor binding.
Labeled / Functionalized Heparin	Biotin-labeled heparin	H464269	Heparin–biotin sodium salt	—	≥97%	Biotin-labeled heparin for pull-down assays, ELISA immobilization, and affinity purification of heparin-binding proteins.
Labeled / Functionalized Heparin	Fluorescein-labeled heparin	F758173	Fluorescein heparin	—	≥99%	Fluorescein (FITC)–labeled heparin for studies of cellular uptake and localization, tissue imaging, and visualization of heparinized surfaces.
Labeled / Functionalized HS	Biotin-labeled HS	B758406	Biotin heparan sulfate sodium salt	—	≥95%	Biotin-labeled HS for studying HS–protein interactions and capturing cell-surface HS.
Labeled / Functionalized HS	Fluorescein-labeled HS	F758385	Fluorescein heparan sulfate	—	≥95%	HS-based fluorescent probe used to compare Hep/HS in terms of cell binding and uptake.
Functionalized Heparin Materials	HepMA (low substitution)	M757066	Methacrylated heparin (HepMA)	—	Methacrylation degree: 5%–25%	Can be copolymerized with acrylate/hydrogel systems to prepare crosslinkable heparin-containing hydrogels for anticoagulant coatings and tissue engineering.
Functionalized Heparin Materials	HepMA (medium to high substitution)	M301780	Methacrylated heparin (HepMA)	—	Degree of substitution: 20%–30%	Higher-substitution HepMA suitable for constructing high-heparin-density functional hydrogels and drug-release carriers.
Heparin Oligosaccharide / Disaccharide Standards	Heparin oligosaccharide mixture	H758655	Heparin oligosaccharide mixture	—	≥95% (HPLC)	Mixture of heparin oligosaccharides used for fingerprinting enzymatic digestion products, quantitative analysis, and structural studies.
Heparin Oligosaccharide / Disaccharide Standards	Heparin tetrasaccharide	H758675	Heparin tetrasaccharide	—	≥95% (HPLC)	Medium-length heparin oligosaccharide for studies of oligosaccharide length on thrombin inhibition, protein binding, etc.
Heparin Oligosaccharide / Disaccharide Standards	Heparin octasaccharide	H758680	Heparin octasaccharide	—	≥95% (HPLC)	Longer heparin oligosaccharide commonly used to study structural features surrounding the ATIII-binding site.
Heparin Oligosaccharide / Disaccharide Standards	Heparin disaccharide	H758662	Heparin disaccharide	—	≥95% (HPLC)	Basic structural unit after enzymatic digestion of heparin/HS, an important standard for LC/LC-MS structural analysis.
Heparin Oligosaccharide / Disaccharide Standards	Heparin disaccharide standard mixture	H759000	Heparin disaccharide standard mixture	—	≥95% (HPLC)	Mixture of disaccharides with multiple sulfation patterns for heparin/HS disaccharide fingerprint analysis.
HS Oligosaccharide / Disaccharide Standards	HS oligosaccharide mixture	H758741	Heparan sulfate oligosaccharide mixture	—	≥95%	HS oligosaccharide mixture used with heparin oligosaccharides for comparative Hep/HS enzymatic digestion profiling.
HS Oligosaccharide / Disaccharide Standards	HS disaccharide standard	H758743	Heparan sulfate disaccharide	—	≥95% (HPLC)	HS disaccharide standard used for HS structural analysis and cleavage site mapping.
Fluorescent Heparin Disaccharide Standards	Fluorescent heparin disaccharide mixture	H760002	Fluorescently labeled heparin disaccharide standard mixture (2-aminobenzamide)	—	≥95% (HPLC)	2-Aminobenzamide–labeled heparin disaccharide mixture for highly sensitive HPLC/UPLC analysis.
Fluorescent Heparin Disaccharide Standards	Fluorescent heparin disaccharide I-A	H760004	Fluorescently labeled heparin disaccharide I-A sodium salt (α-ΔUA-2S-[1→4]-GlcNAc-6S) (2-aminobenzamide)	136098-00-5 (unlabeled)	≥95% (HPLC)	Structurally defined fluorescent heparin disaccharide used as a single standard to calibrate retention time or study specific structures in protein binding.
Heparin Affinity Media / Probes / Peptides	Heparin affinity chromatography medium	H1492530	Heparin affinity chromatography medium	—	BioReagent, endotoxin tested, 50% v/v	Prepacked heparin affinity medium for purification of heparin-binding proteins (such as growth factors and coagulation factors).
Heparin Affinity Media / Probes / Peptides	Heparin-specific protein probe	H758291	Heparin-specific protein probe	—	1 mg/mL	Heparin-specific probe used to detect heparin/HS in samples or to label heparinized surfaces.
Heparin Affinity Media / Probes / Peptides	Heparin-binding peptide I	H274982	Heparin-binding peptide I	—	≥95%	Synthetic heparin-binding peptide used to study protein–heparin interaction interfaces or to construct heparin recognition modules.
Heparin / HS Lyases	Heparinase I	H766335	Heparinase I	9025-39-2	Bioactive, ActiBioPure™, EnzymoPure™, high performance, ≥90% (SDS-PAGE), ≥6000 U/mL	Selective tool enzyme for cleaving heparin/HS to generate oligosaccharides with unsaturated uronic acids for structural analysis.
Heparin / HS Lyases	Heparinase II	H766338	Heparinase II	149371-12-0	Bioactive, ActiBioPure™, high performance, EnzymoPure™, ≥90% (SDS-PAGE), ≥2400 U/mL	Heparinase used with I/III, with distinct cleavage preferences for specific sulfation patterns.
Heparin / HS Lyases	Heparinase III	H766341	Heparinase III	37290-86-1	ActiBioPure™, bioactive, EnzymoPure™, high performance, ≥90% (SDS-PAGE), ≥3000 U/mL	More selective for HS, commonly used to distinguish structural differences between Hep and HS.
Heparin / HS Lyases	Heparinase mixture I/II/III	H766343	Heparinases I, II, and III mixture	—	EnzymoPure™, ≥200 U/mg, from Flavobacterium heparinum	Multi-enzyme mixture enabling broad digestion of Hep/HS to obtain complete disaccharide/oligosaccharide profiles.
Heparanase and Inhibitors	Human heparanase-1	H1435491	Human heparanase-1	—	—	Key HS/heparin-degrading enzyme (heparanase-1) involved in extracellular matrix remodeling and tumor invasion.
Heparanase and Inhibitors	Heparanase inhibitor OGT 2115	O288697	OGT 2115, heparanase inhibitor	853929-59-6	≥97% (HPLC)	Selective heparanase inhibitor used with human heparanase-1 to study Hep/HS metabolic regulation and antitumor effects.
Heparin Anticoagulated Plasma	Balb/c mouse plasma (heparin anticoagulated)	B1371693	Balb/c mouse plasma (heparin sodium anticoagulated)	—	BioReagent, sterile	Balb/c mouse plasma anticoagulated with heparin sodium, used in thrombosis and inflammation experiments in murine models.
Heparin Anticoagulated Plasma	Rat plasma (heparin anticoagulated)	R774378	Rat plasma (heparin sodium anticoagulated)	—	BioReagent, sterile	Heparin anticoagulated rat plasma commonly used in rat thrombosis/coagulation studies.
Heparin Anticoagulated Plasma	Mouse plasma (heparin anticoagulated)	M774390	Mouse plasma (heparin sodium anticoagulated)	—	BioReagent, sterile	Conventional mouse heparin anticoagulated plasma for controls and method validation.
Heparin Anticoagulated Plasma	Pig plasma (heparin anticoagulated)	P1371695	Pig plasma (heparin sodium anticoagulated)	—	BioReagent, sterile	Porcine heparin anticoagulated plasma suitable for in vitro experiments in large-animal or preclinical models.
Heparinoid / Precursors	Heparinoid (heparinoid)	H283846	Heparinoid	391208-81-4	—	Heparinoid product structurally similar to heparin, used for comparative studies of the biological activity of heparin-like compounds.
Heparinoid / Precursors	Heparin precursor	H1455956	Heparin precursor	—	—	Used in the synthesis/modification of heparin or heparin derivatives, representing the “upstream intermediate” category.

Aladdin: https://www.aladdinsci.com/